Atrial Standstill

Definition

Atrial standstill (AS) is the complete absence of atrial electrical and mechanical activity, caused by diffuse atrial myocardial disease. The defining feature is atrial inexcitability: intracardiac recordings show no atrial electrograms, and pacing at maximal output (≥10 mA, 2 ms) fails to capture. This is what separates AS from sinus node dysfunction — in SND the atrial myocardium is diseased but still excitable and still captures. (sources/atrial-standstill-hrs-2026, rating: medium)

It is a syndrome, not a single disease. At least three independent molecular pathways converge on the same electrical silence — ion channel/gap junction (SCN5A ± GJA5), natriuretic peptide (NPPA), and nuclear envelope (EMD, LMNA) — and each produces a different histology, a different natural history and a different device decision. Within the EHRAS classification of atrial cardiomyopathies, AS is best understood as the end-stage of fibrotic atrial cardiomyopathy (classes II–III), and the debate over whether it is a distinct entity or the extreme end of a spectrum remains open.

Terminology — the words carry management consequences:

Key Concepts

• It is mistaken for AF with a slow ventricular response, not for a bradyarrhythmia. The combination that should trigger the thought is a slow, regular junctional or ventricular rhythm with no P waves in any lead, absent A waves on echo, and a patient who is on no AV-nodal blocking drug.
• The atrium is electrically dead but anatomically present — dilated, often to giant dimensions, and capable of causing severe functional MR/TR through annular dilatation.
• Thromboembolism, not bradycardia, is what kills. Rates run 22–54% across etiologies, and conventional AF risk scores predict an order of magnitude less than the observed risk in young patients.
• Excitability is the diagnostic line. Everything else — absent P waves, absent A wave, silent voltage map — supports the diagnosis; only failure of atrial capture at maximal output proves it.
• Genotype dictates the device, not the diagnosis. The EMD–LMNA divergence (AS and conduction disease versus ventricular arrhythmia and sudden death) is the single most actionable discrimination in the field.

Epidemiology and Presentation

• No population prevalence is known. Published series are inflated toward severe phenotypes because entry requires electrophysiological confirmation.
• Age and sex track etiology. Autosomal recessive NPPA presents in adulthood with age-dependent penetrance; X-linked EMD affects predominantly males (~80%); autosomal dominant LMNA shows female predominance in some series (73%); SCN5A-related congenital AS affects males from infancy to adolescence; idiopathic fibrotic atrial cardiomyopathy presents at 46 ± 13 years. (sources/atrial-standstill-hrs-2026, rating: medium)
• Palpitations are the most common presenting symptom (~54% in the NPPA series), from the atrial tachyarrhythmias that precede standstill. Dyspnoea is usually mild (NYHA I–II).
• Syncope comes from severe bradycardia or prolonged pauses — Holter has recorded RR intervals of 5.42–6.65 s and episodes of 10–15 s of ventricular asystole.
• Stroke or TIA is the presenting manifestation in 8% of NPPA and 22% of EDMD patients, and has occurred in a 7-year-old.
• Bradycardia with absent "a" waves on the jugular venous pulse is near-universal, and is the bedside sign most likely to be noticed.

ECG and the Evolutionary Sequence

The end-stage ECG is a regular junctional escape at 30–55 bpm, or a ventricular escape at 30–40 bpm with QRS ≥0.12 s, with no P waves in any of the 12 leads. In incomplete AS the junctional rhythm may be irregular, with residual low-amplitude atrial activity confined to the septum.

• QRS is typically normal in isolated atrial disease. Bundle branch block and a prolonged HV interval indicate His-Purkinje involvement — common with SCN5A, and the reason pacing mode decisions cannot be made from the ECG alone. (sources/atrial-standstill-hrs-2026)
• An absent A wave alone proves nothing. It also occurs in AF, junctional rhythm and post-cardioversion atrial stunning.

Why the Atrium Goes Silent — Three Pathways

SCN5A — the exit-block hypothesis. Nav1.5 loss of function produces reduced peak I_Na, a hyperpolarising shift of inactivation, slowed recovery and haploinsufficiency. Because sinus node pacemaking depends primarily on Ca²⁺ channels, the lesion is proposed to be failure of impulse conduction from the sinus node into atrial myocardium rather than failure of automaticity — though this remains experimentally unconfirmed. SCN5A LOEUF (0.42) sits above the haploinsufficiency threshold, meaning heterozygous loss of function is tolerated in the general population; clinical disease likely needs a second hit. (sources/atrial-standstill-hrs-2026, rating: medium)

The digenic model. Two GJA5 (connexin 40) promoter polymorphisms in complete linkage disequilibrium cut Cx40 promoter activity below 50%. Full expression occurred only in individuals carrying both an SCN5A mutation and the Cx40 polymorphisms — in 2 families, never independently replicated.

NPPA — the non-ion-channel route. Homozygous p.Arg150Gln abolishes ANP signalling and produces primary atrial dilated cardiomyopathy: adult-onset biatrial dilatation to giant dimensions (RA up to 744 mL), early tachyarrhythmias, progression to complete AS, and long-term preserved LV function (LVEF 54–74%). It is the clearest demonstration that AS can be a myocardial disease rather than an electrical one.

EMD and LMNA — the divergence that matters.

• EMD (emerin, Xq28) is associated with AS in 46.7% of carriers, and 33% of all reported AS cases are attributable to EDMD. AF/flutter precedes AS in 61%, and 45% of those with AF/flutter progress to AS. ICD requirement is low (3.3%).
• LMNA (lamins A/C, 1q21) is associated with AS in 0% of the Marchel cohort — though reported elsewhere — and is dominated by ventricular arrhythmia (nsVT/VT 60%) with high ICD requirement (60%). SCD accounts for 46% of deaths.
• Both cause conduction disease and AF, so the distinguishing question is not "does this patient have a laminopathy or an emerinopathy" but "do I need to protect against ventricular arrhythmia or against atrial silence."

Diagnosis

Diagnosis is a two-step process: suspect on non-invasive testing, prove invasively.

Step 1 — suspicion.

• Echocardiography is first-line. The triad is absent A wave on mitral/tricuspid inflow Doppler, absent atrial wall motion on M-mode/2D, and biatrial dilatation. Each element is individually nonspecific; the triad is not.
• CT is the anatomical gold standard for atrial volume (complete AS: LA 253 mL/m², RA 443 mL/m² — CT volumes exceed echo).
• LGE-MRI shows biatrial wall enhancement consistent with diffuse fibrosis, and its most useful contribution may be a negative one: ventricular LGE was absent in all 21 patients imaged, which argues against an accompanying ventricular cardiomyopathy.
• Exclude the reversible mimics first: serum potassium (hyperkalaemia is the most common reversible cause), thyroid function, drugs (digitalis), recent cardiac surgery, and myocarditis.

Step 2 — confirmation.

• Intracardiac recordings showing absent atrial electrograms, plus failure of atrial capture at 10 mA, 2 ms, at multiple sites. This is the diagnostic standard and the reason the literature is skewed toward advanced disease.
• Electroanatomic mapping grades severity through three voltage tiers (normal >0.5 mV; low voltage 0.1–0.5 mV; scar <0.05–0.1 mV) and maps the canonical progression — high lateral RA → mid-lateral RA → low lateral RA → interatrial septum → peritricuspid annulus → coronary sinus ostium. Individual variation is common; other series localise RA silence posterolaterally and LA silence anteriorly.
• Surviving islands matter. Residual atrial tissue, sometimes only unmasked by isoproterenol, can sustain organised atrial tachycardia, and the coronary sinus musculature can act as an isolated "fifth chamber" driving flutter or fibrillation that cannot be conducted to the inert right atrium.

Differential Diagnosis

Acquired causes deserve specific effort because they are the only reversible ones: cardiac amyloidosis (AL and ATTR) may alter systemic therapy even though tafamidis has not been studied for AS; myocarditis may reverse with immunosuppression, with serial ECG and Holter at 1, 3 and 6 months suggested; Chagas disease in endemic regions; cardiac sarcoidosis; and extensive AF ablation, which can produce isolated LA standstill with a preserved RA.

Complications

Thromboembolism is the dominant risk, and it is not predicted by CHA₂DS₂-VASc.

• Rates: EDMD/LMNA 22%; NPPA 54%; familial endemic AS ~30%; 35% in a paediatric multicentre series over a median 6.9 years. (sources/atrial-standstill-hrs-2026, rating: medium)
• The mechanism is etiology-specific and prothrombotic, not merely stasis. LMNA carriers have increased thrombin generation and abnormal platelet function independent of atrial arrhythmia and LVEF (HR 4.8). More broadly, isolated sinus node dysfunction independently raises ischaemic stroke risk (subdistribution HR 2.28), and sick sinus syndrome raises stroke risk in AF with low CHA₂DS₂-VASc scores (HR 2.13) — atrial electrical disease confers thromboembolic risk independently of AF.
• The arithmetic is the argument. Untreated AS accrues a 33–54% cumulative burden, which is what a CHA₂DS₂-VASc of 8–9 gives an AF patient over 3–5 years. Yet most AS patients score 0–2, where AF predicts 0.2–0.6% per year against an observed ~5% per year.
• Antiplatelet therapy has failed in practice — strokes occurred in patients taking aspirin.

Heart failure is etiology dependent. LMNA carriers progress (LVEF ≤50% rising from 44% to 57%; end-stage HF in 19%); NPPA patients do not (LVEF 54–74% over 37 years). Three mechanisms operate: loss of the atrial booster pump (20–30% of ventricular end-diastolic volume), giant atrial dilatation causing annular dilatation with severe MR/TR, and VVI pacing-associated AV dyssynchrony.

Sudden cardiac death is genotype specific — 46% of deaths in LMNA, low in EMD (nsVT/VT 6.7%), undetermined in NPPA (4 sudden deaths without documented arrhythmia or autopsy), and high with biallelic SCN5A (major cardiac events 50%, mortality 15% at a mean age of 9). In biallelic SCN5A disease, haemodynamic collapse can occur without arrhythmia or device failure, which places it outside a purely rhythm-based model of sudden death.

Supraventricular arrhythmias are common early and are part of the disease, not a separate problem: 80% of children in one series had atrial or supraventricular arrhythmias, and AF/flutter precedes AS in 61% of EDMD.

Management

Pacing.

• Symptomatic bradycardia mandates permanent pacing — uniformly endorsed, though a no-pacing comparator is ethically impossible.
• Complete AS: VVI/VVIR is the default, because there is no atrial tissue to capture.
• Partial AS: EAM-guided atrial lead placement at a viable site can achieve DDD pacing and reduce the right ventricular pacing burden from 100% to 4–19%. Dual-chamber pacing via the proximal coronary sinus has also been reported.
• Atrial leads fail. Progressive loss of sensing and capture within 3–8 years is common across etiologies, so these patients need lead surveillance, not a one-off implant.
• LBBAP rests on a single case report and carries a theoretical concern about septal pacing in pre-existing His-Purkinje disease. Leadless pacemakers are VVI-only, may suit 15–20%, and giant RA anatomy can make implantation difficult.

ICD — decided by gene, not by AS.

Anticoagulation. Confirmed complete AS warrants anticoagulation across all etiologies — the authors would not withhold it on the basis of etiology alone, and reserve monitoring off anticoagulation for a contraindication or prohibitive bleeding risk. Warfarin at INR 2–3 or a NOAC, started at diagnosis, for any documented atrial tachyarrhythmia or AS regardless of conventional risk scores.

• NOAC use is off-label and extrapolated from AF; there are no AS-specific data.
• Paediatric patients face warfarin management in a growing child plus cumulative bleeding risk; dabigatran and rivaroxaban are FDA-approved from 2021 for paediatric venous thromboembolism, but no paediatric AS data exist.
• Periprocedurally, uninterrupted or minimally interrupted anticoagulation is preferred for device implantation (BRUISE CONTROL). If TEE shows spontaneous echo contrast or LA appendage thrombus, anticoagulate regardless of etiology.

Genetic counselling is where the diagnosis becomes actionable for a family. Inheritance ranges from autosomal dominant with 50% first-degree risk (LMNA, SCN5A) through autosomal recessive with 25% sibling risk (NPPA) to X-linked, where all daughters of an affected male are obligate carriers. Details are tabulated on concepts/Cascade-Family-Screening.

Contradictions / Open Questions

• Is atrial standstill an entity or the end of a spectrum? The review argues it is the most extreme manifestation of fibrotic atrial cardiomyopathy (EHRAS II–III), yet also treats it as a recognisable syndrome with uniform diagnostic criteria. The practical resolution offered — syndrome for diagnosis and anticoagulation, spectrum for device and family decisions — is a reasonable working compromise, not a settled classification. (sources/atrial-standstill-hrs-2026, rating: medium)
• Whether atrial standstill is rare, or rarely diagnosed. Every published estimate is conditioned on electrophysiological confirmation, which selects advanced, irreversible disease. Partial AS is probably commoner and possibly more benign; until a registry captures suspected-but-unconfirmed cases, the natural history of the milder end is unknown.
• Which connexin the digenic model actually implicates. The SCN5A + Cx40 (GJA5) model is the one described in the primary literature and in this review, but the principal SCN5A review in this wiki describes the co-inherited polymorphism as connexin 43 — a different gene (GJA1) at a different gap junction. The two cannot both be right, and 20 years without independent replication means the whole model rests on 2 families. (sources/scn5a-jaccep-2018, rating: high; sources/atrial-standstill-hrs-2026)
• How often LMNA causes atrial standstill. The wiki's LMNA page, drawn from a DCM review, lists AS as part of the laminopathy phenotype; the largest head-to-head cohort found AS in 0 of 15 LMNA carriers against 46.7% of EMD carriers. The likeliest reading is that AS is characteristic of emerinopathy and exceptional in laminopathy — but "exceptional" and "absent" have very different implications for family counselling.
• Whether atrial pacing prevents thromboembolism. The hypothesis is attractive and the paediatric data are suggestive (none of 7 patients with TEs had functional atrial pacing), but only 4 of 15 attempted atrial leads achieved capture. The question cannot be answered without a registry.
• Why patients with NPPA disease die suddenly. Four out-of-hospital sudden deaths occurred without documented ventricular arrhythmia, and without autopsy the arrhythmic and thromboembolic explanations cannot be separated — so no rational ICD recommendation can be made for this genotype.
• Whether SCN5A-related AS has structural histology. The exit-block hypothesis predicts a purely electrical lesion, but this has never been histologically confirmed. If SCN5A AS turns out to have structural atrial degeneration, the "three pathways converge on one pathology" model loses its cleanest example.
• No randomised evidence exists for any intervention. Anticoagulation, pacing mode, ICD selection and EAM-guided lead placement all rest on case series. The proposed international registry with tiered enrolment (confirmed, suspected, asymptomatic carriers) is the field's most concrete remedy.

Connections

• The excitability-based differential: concepts/Sinus-Node-Dysfunction — SND is the condition AS is most often confused with, and the pacing-capture distinction is what separates them
• The spectrum it sits at the end of: concepts/Atrial-Cardiomyopathy · concepts/Atrial-Failure — AS as EHRAS class II–III end-stage
• Where the diagnosis changes management: concepts/Permanent-Pacing-Indications — VVI in complete AS, EAM-guided DDD in partial AS
• The genes: entities/SCN5A · entities/EMD · entities/NPPA · entities/LMNA — three pathways, three device strategies
• The overlap syndrome: entities/Brugada-Syndrome — the same SCN5A variant can produce BrS, LQT3, conduction disease or AS in one family
• The acquired mimics: entities/ATTR-Amyloidosis · entities/AL-Amyloidosis — infiltrative AS may alter systemic therapy
• What it causes: concepts/Sudden-Cardiac-Death · entities/ICD — genotype-specific SCD risk
• How it is imaged: concepts/Late-Gadolinium-Enhancement — biatrial fibrosis, and the value of a negative ventricular study
• What happens to the family: concepts/Cascade-Family-Screening — 50% autosomal dominant, 25% recessive, X-linked carrier daughters

Sources

• sources/atrial-standstill-hrs-2026
• sources/scn5a-jaccep-2018
• sources/atrial-cmp-esc-2025
• sources/genetic-af-cjc-2024
• sources/DCM-Lancet-2023